Date | Title | Description | Source |
29.02.2024 | Verona Pharma Reports Fourth Quarter and Full Year 2023 Fina... | PDUFA Target Action Date for ensifentrine of June 26, 2024
Commercialization preparations advance
St... | einpresswi... |
20.07.2023 | Verona Pharma to Report Second Quarter 2023 Financial Result... | /EIN News/ -- LONDON and RALEIGH, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq:... | einpresswi... |
28.06.2023 | Nuance Pharma's Partner Verona Pharma Submits New Drug Appli... | SHANGHAI, June 28, 2023 /PRNewswire/ -- Nuance Pharma announces its partner, Verona Pharma plc (Nasd... | en.prnasia... |
27.06.2023 | Verona Pharma Submits New Drug Application to US FDA for Ens... | /EIN News/ -- LONDON and RALEIGH, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq:... | einpresswi... |
24.05.2023 | Verona Pharma to Present at Jefferies Healthcare Conference | /EIN News/ -- LONDON and RALEIGH, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: ... | einpresswi... |
02.05.2023 | Verona Pharma to Present Expanded Analyses of Positive Phase... | 12 Abstracts and one Symposium further support potential of ensifentrine,
a first-in-class, selectiv... | einpresswi... |
07.04.2023 | Nuance Pharma Announces Dosing of First Patient in ENHANCE -... | SHANGHAI, April 7, 2023 /PRNewswire/ -- Nuance Pharma ("the Company") announces dosing of ... | en.prnasia... |
07.04.2023 | Nuance Pharma Announces Dosing of First Patient in ENHANCE -... | SHANGHAI, April 6, 2023 /PRNewswire/ -- Nuance Pharma ("the Company") announces dosing of ... | einpresswi... |
20.12.2022 | Verona Pharma Announces Ensifentrine Meets Primary and Key S... | Statistically significant improvements in lung function, symptoms and quality of life
36% reduction ... | einpresswi... |
09.11.2022 | Verona Pharma Reports Third Quarter 2022 Financial Results a... | /EIN News/ -- Access to up to $400 million expected to provide cash runway through at least 2025
Top... | einpresswi... |
26.10.2022 | Verona Pharma to Report Third Quarter 2022 Financial Results... | LONDON and RALEIGH, N.C., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | globenewsw... |
17.10.2022 | Verona Pharma Secures Debt Financing of up to $150 Million f... | LONDON and RALEIGH, N.C., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | globenewsw... |
29.08.2022 | Verona Pharma to Present at H.C. Wainwright 24th Annual Glob... | LONDON and RALEIGH, N.C., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | globenewsw... |
24.08.2022 | Verona Pharma strengthens commercialization leadership team | LONDON and RALEIGH, N.C., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | globenewsw... |
19.08.2022 | Nuance Pharma receives Clearance to begin Pivotal Clinical T... | LONDON and RALEIGH, N.C., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | globenewsw... |
19.08.2022 | Nuance Pharma receives Clearance to begin Pivotal Clinical T... | LONDON and RALEIGH, N.C., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc VRNA ("Verona Pha... | einpresswi... |
19.08.2022 | Nuance Pharma Announces Clearance of IND Application for Ens... | SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the Center... | einpresswi... |
19.08.2022 | Nuance Pharma Announces Clearance of IND Application for Ens... | SHANGHAI, Aug. 19, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the Center... | en.prnasia... |
15.08.2022 | Verona Pharma plc Announces Closing of Upsized Underwritten ... | LONDON and RALEIGH, N.C., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | globenewsw... |
10.08.2022 | Verona Pharma plc Announces Pricing of Upsized Underwritten ... | LONDON and RALEIGH, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | globenewsw... |
09.08.2022 | Verona Pharma Reports Second Quarter 2022 Financial Results ... | Ensifentrine met primary and secondary endpoints of evaluating lung function in Phase 3 ENHANCE-2 tr... | globenewsw... |
09.08.2022 | Verona Pharma plc Announces Proposed Underwritten Public Off... | LONDON and RALEIGH, N.C., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | globenewsw... |
09.08.2022 | Verona Pharma Announces Ensifentrine Meets Primary Endpoint ... | Statistically significant improvements in key measures of lung function
42% reduction in rate of exa... | globenewsw... |
08.08.2022 | Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE... | LONDON and RALEIGH, N.C., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | globenewsw... |
29.07.2022 | Verona Pharma to Report Second Quarter 2022 Financial Result... | LONDON and RALEIGH, N.C., July 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | globenewsw... |
09.06.2022 | Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Tria... | LONDON and RALEIGH, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | globenewsw... |
06.06.2022 | Verona Pharma to Host KOL Event on June 16, 2022 | LONDON and RALEIGH, N.C., June 06, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | globenewsw... |
25.05.2022 | Verona Pharma to Present at Jefferies Healthcare Conference | LONDON and RALEIGH, N.C., May 25, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona... | globenewsw... |
09.05.2022 | Verona Pharma to Present Successful TQT Analysis Demonstrati... | LONDON and RALEIGH, N.C., May 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona... | globenewsw... |
04.05.2022 | Verona Pharma Announces May 2022 Investor Conference Partici... | LONDON and RALEIGH, N.C., May 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona... | globenewsw... |
03.05.2022 | Verona Pharma Reports First Quarter 2022 Financial Results a... | Phase 3 ENHANCE-2 trial on target to report top-line COPD data in Q3 2022
James Brady joined the Boa... | globenewsw... |
19.04.2022 | Verona Pharma to Report First Quarter 2022 Financial Results... | LONDON and RALEIGH, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Vero... | globenewsw... |
14.03.2022 | James Brady Joins Verona Pharma as Non-Executive Director | LONDON and RALEIGH, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Vero... | globenewsw... |
03.03.2022 | Verona Pharma Reports Fourth Quarter and Full Year 2021 Fina... | Phase 3 ENHANCE program on track to report top-line COPD data in 2022
Conference call today at 9:00 ... | globenewsw... |
17.02.2022 | Verona Pharma to Report Fourth Quarter and Full Year 2021 Fi... | LONDON and RALEIGH, N.C., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | globenewsw... |
24.01.2022 | Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Tria... | Top-line Data Expected in the Third Quarter of 2022
LONDON and RALEIGH, N.C., Jan. 24, 2022 (GLOBE N... | marketscre... |
24.01.2022 | Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Tria... | LONDON and RALEIGH, N.C., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | globenewsw... |
05.01.2022 | Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subs... | ENHANCE-2 Screening Complete with Full Enrollment Expected in January 2022
ENHANCE Phase 3 Program o... | globenewsw... |
05.01.2022 | Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subs... | ENHANCE-2 Screening Complete with Full Enrollment Expected in January 2022
ENHANCE Phase 3 Program o... | marketscre... |
04.01.2022 | Verona Pharma to Present at H.C. Wainwright BioConnect Virtu... | LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | marketscre... |
04.01.2022 | Verona Pharma to Present at H.C. Wainwright BioConnect Virtu... | LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | globenewsw... |
16.12.2021 | Verona Pharma Reports TQT Study Successfully Demonstrated No... | LONDON and RALEIGH, N.C., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | globenewsw... |
16.12.2021 | Verona Pharma Reports TQT Study Successfully Demonstrated No... | Study Supports Ongoing Phase 3 Program and Planned NDA Submission
LONDON and RALEIGH, N.C., Dec. 16,... | marketscre... |
09.11.2021 | Verona Pharma Reports Third Quarter 2021 Financial Results a... | Enrollment in ENHANCE-1 48-week subset and ENHANCE-2 expected to complete around year-end 2021
ENHAN... | globenewsw... |
01.11.2021 | Verona Pharma Announces November 2021 Investor Conference Pa... | LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | marketscre... |
01.11.2021 | Verona Pharma Announces November 2021 Investor Conference Pa... | LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | globenewsw... |
26.10.2021 | Verona Pharma to Report Third Quarter 2021 Financial Results... | LONDON and RALEIGH, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | globenewsw... |
13.10.2021 | Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine... | LONDON and RALEIGH, N.C., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | globenewsw... |
13.10.2021 | Verona Pharma : to Present Phase 2 Data with pMDI Ensifentri... | Bronchodilation demonstrated with pMDI, consistent with DPI and nebulizer formulations
LONDON and RA... | marketscre... |
05.08.2021 | Verona Pharma Reports Second Quarter 2021 Financial Results ... | ENHANCE Phase 3 program on track to report top-line data in 2022
Up to $219 million strategic collab... | marketscre... |
27.07.2021 | Verona Pharma Announces August 2021 Virtual Investor Confere... | LONDON and RALEIGH, N.C., July 27, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | marketscre... |
22.07.2021 | Verona Pharma to Report Second Quarter 2021 Financial Result... | LONDON and RALEIGH, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | marketscre... |
10.06.2021 | Verona Pharma and Nuance Pharma Announce $219 Million Strate... | LONDON and RALEIGH, N.C., and SHANGHAI, June 10, 2021 /PRNewswire/ -- Verona Pharma plc (Nasdaq: VRN... | en.prnasia... |
25.05.2021 | VERONA PHARMA PLC
Verona Pharma to Present at Jefferies Vir... | LONDON and RALEIGH, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona... | marketscre... |
04.05.2021 | VERONA PHARMA PLC
Verona Pharma to Present Expanded Analysi... | LONDON and RALEIGH, N.C., May 04, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona... | marketscre... |
29.04.2021 | VERONA PHARMA PLC
Verona Pharma Reports First Quarter 2021 ... | ENHANCE Phase 3 program enrollment continues on track to complete in 2H21
Board strengthened with NE... | marketscre... |
27.04.2021 | VERONA PHARMA PLC
Verona Pharma Announces Publication of Ph... | LONDON and RALEIGH, N.C., April 27, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Vero... | marketscre... |
23.04.2021 | VERONA PHARMA PLC
Verona Pharma Reports Results of Pilot St... | LONDON and RALEIGH, N.C., April 23, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Vero... | marketscre... |
21.04.2021 | VERONA PHARMA PLC
Verona Pharma to Report First Quarter 202... | LONDON and RALEIGH, N.C., April 21, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Vero... | marketscre... |
02.03.2021 | Lisa Deschamps Joins Verona Pharma as Non-Executive Director | LONDON and RALEIGH, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Vero... | globenewsw... |
01.03.2021 | Verona Pharma to Present at H.C. Wainwright Global Life Scie... | LONDON and RALEIGH, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Vero... | globenewsw... |
18.02.2021 | Verona Pharma to Report Fourth Quarter and Full Year 2020 Fi... | LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | globenewsw... |
18.02.2021 | VERONA PHARMA PLC
Verona Pharma to Report Fourth Quarter an... | LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | marketscre... |
02.02.2021 | VERONA PHARMA PLC
Verona Pharma Reports Positive Phase 2 Re... | Primary and secondary lung function endpoints met
Results support twice-daily dosing
LONDON and RALE... | marketscre... |
02.02.2021 | VERONA PHARMA PLC
CORRECTING and REPLACING -- Verona Pharma... | LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headl... | marketscre... |
14.01.2021 | VERONA PHARMA PLC
Verona Pharma Completes Enrollment in Pil... | LONDON and RALEIGH, N.C., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | marketscre... |
05.01.2021 | VERONA PHARMA PLC
Verona Pharma to Present at H.C. Wainwrig... | LONDON and RALEIGH, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | marketscre... |
24.11.2020 | Verona Pharma : Secures up to $30 Million Debt Financing fro... | LONDON - Verona Pharma plc (Nasdaq: VRNA) ('Verona Pharma' or the 'Company'), a clinical-stage bioph... | marketscre... |
24.11.2020 | VERONA PHARMA PLC
Verona Pharma : Secures up to $30 Million... | LONDON - Verona Pharma plc (Nasdaq: VRNA) ('Verona Pharma' or the 'Company'), a clinical-stage bioph... | marketscre... |
23.11.2020 | Verona Pharma Secures up to $30 Million Debt Financing from ... | - | orbimed.co... |
23.11.2020 | VERONA PHARMA PLC
Verona Pharma : Secures up to $30 Million... | Non-dilutive capital to provide further financial flexibility
LONDON and RALEIGH, N.C., Nov. 23, 202... | marketscre... |
23.11.2020 | Verona Pharma : Secures up to $30 Million Debt Financing fro... | Non-dilutive capital to provide further financial flexibility
LONDON and RALEIGH, N.C., Nov. 23, 202... | marketscre... |
09.11.2020 | VERONA PHARMA PLC
Verona Pharma : Announces November 2020 V... | LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | marketscre... |
09.11.2020 | VERONA PHARMA PLC
Verona Pharma Announces November 2020 Vir... | LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... | marketscre... |
28.10.2020 | VERONA PHARMA PLC
Verona Pharma plc : Update on AIM Delisti... | LONDON and RALEIGH, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VR... | marketscre... |
22.10.2020 | VERONA PHARMA PLC
Verona Pharma to Announce Interim Results... | LONDON and RALEIGH, N.C., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VR... | marketscre... |
21.09.2020 | VERONA PHARMA PLC
Verona Pharma : Intended Delisting and Ca... | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGU... | marketscre... |
17.09.2020 | Verona Pharma Raises $200Million in Oversubscribed Private P... | - | vivocapita... |
17.07.2020 | VERONA PHARMA PLC
Verona Pharma Raises $200 Million in Over... | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGU... | marketscre... |
17.07.2020 | Verona Pharma Raises $200 Million in Oversubscribed Private ... | - | abingworth... |
13.01.2020 | PACT Pharma bags $75M for neoantigen TCR work, manufact... | → With a new president and chief technical officer in place, next-gen T cell therapy player... | endpts.com... |
27.04.2017 | Term Sheet — Thursday, April 27 | PETER PAN NEVER HAD TO GROW UP
The following article is from Fortune’s latest issue.
Paid Content Wh... | fortune.co... |
04.04.2017 | Allergan vet takes the CEO’s job at Third Rock’s Relay; V... | Sanjiv Patel
→ Third Rock Ventures has recruited Allergan’s chief strategy officer, Sanj... | endpts.com... |
04.04.2017 | Verona files for $86M IPO to fund COPD, cystic fibrosis tria... | Verona Pharma has filed to raise up to $86 million (€81 million) through a Nasdaq IPO. The British r... | fiercebiot... |
20.06.2016 | Verona raises £45M from A-list backers for PhIIb COPD trial,... | Verona Pharma (LON:VRP) has secured £44.7 million ($65.6 million) from big-name investors on both si... | fiercebiot... |